webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Amino-PEG4-Val-Cit-PAB-MMAE

  CAS No.: 1492056-71-9   Cat No.: BADC-00958   Purity: >98.0% 4.5  

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Amino-PEG4-Val-Cit-PAB-MMAE

Structure of 1492056-71-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C69H115N11O17
Molecular Weight
1370.71
Shipping
Room temperature
Shipping
Store at -20 °C, keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
HY-141154; CS-0114459
IUPAC Name
[4-[[(2S)-2-[[(2S)-2-[3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-2-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methylbutanoyl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
Canonical SMILES
CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(C(C)C)C(=O)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCOCCOCCOCCOCCN
InChI
InChI=1S/C69H115N11O17/c1-15-46(8)60(54(91-13)41-56(82)80-32-20-24-53(80)62(92-14)47(9)63(84)73-48(10)61(83)50-21-17-16-18-22-50)78(11)58(44(4)5)66(87)77-67(88)59(45(6)7)79(12)69(90)97-42-49-25-27-51(28-26-49)74-64(85)52(23-19-31-72-68(71)89)75-65(86)57(43(2)3)76-55(81)29-33-93-35-37-95-39-40-96-38-36-94-34-30-70/h16-18,21-22,25-28,43-48,52-54,57-62,83H,15,19-20,23-24,29-42,70H2,1-14H3,(H,73,84)(H,74,85)(H,75,86)(H,76,81)(H3,71,72,89)(H,77,87,88)/t46-,47+,48+,52-,53-,54+,57-,58-,59-,60-,61+,62+/m0/s1
InChIKey
LWOCEMRRZJTWLO-SFLKBQQHSA-N
Solubility
10 mm in DMSO
Shelf Life
-20°C 3 years powder; -80°C 2 years in solvent
Shipping
Room temperature
Storage
Store at -20 °C, keep in dry and avoid sunlight.

Amino-PEG4-Val-Cit-PAB-MMAE, a pivotal linker-drug conjugate, is commonly harnessed in the development of antibody-drug conjugates (ADCs) for precision cancer therapy. Here are four key applications presented with heightened perplexity and burstiness:

ADCs Development: Amino-PEG4-Val-Cit-PAB-MMAE plays a crucial role in crafting potent and selective ADCs designed to target specific cancer cells. The linker facilitates the secure attachment of MMAE, a potent cytotoxic agent, to the antibody, enabling targeted delivery to malignant tissues. This strategy not only minimizes systemic toxicity but also maximizes antitumor efficacy, leading to a paradigm shift in cancer treatment precision.

Cancer Research: In the realm of preclinical cancer investigations, this compound stands as a cornerstone for assessing the efficacy and safety of novel ADCs. Utilizing this linker-drug conjugate, researchers conduct comprehensive in vitro and in vivo experiments to evaluate its impact on tumor dynamics and survival rates. The insights gained aid in pinpointing promising ADC candidates for further escalations into clinical development, fueling advancements in personalized oncology care.

Pharmaceutical Analysis: Amino-PEG4-Val-Cit-PAB-MMAE finds its niche in quality control and analytical scrutiny, ensuring the stability and bioactivity of ADCs. Leveraging sophisticated analytical methodologies such as mass spectrometry and HPLC, experts monitor the conjugation efficiency and purity of ADCs with precision. This meticulous oversight guarantees the consistent performance and safety profile of drug candidates, paving the way for reliable therapeutic interventions.

Targeted Drug Delivery Systems: Beyond the realms of cancer therapy, the versatility of Amino-PEG4-Val-Cit-PAB-MMAE extends to tailored drug delivery systems for diverse therapeutic agents. Through conjugating various bioactive molecules to the linker, researchers engineer innovative drug delivery platforms for a spectrum of disease domains. This application broadens the horizons of this compound, ushering in a new era of targeted therapeutic interventions across multifaceted medical landscapes.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Boc-Ser(O-propargyl)-OH | m-PEG2-NHS ester | MC-Gly-Gly-Phe-Boc | MC-Gly-Gly-Phe-Gly | TCO-GK-PEG4-NHS ester | Fmoc-Val-Ala-PAB-PFP | MMAD | SPDMB | 2,5-dioxopyrrolidin-1-yl 15-(2,5-dioxo-2H-pyrrol-1(5H)-yl)-13-oxo-3,6,9-trioxa-12-azapentadecan-1-oate | 4-succinimidyl-oxycarbonyl-α-(2-pyridyldithio)toluene | Amino-PEG4-Val-Cit-PAB-MMAE
Send Inquiry
Verification code
Inquiry Basket